Trials / Completed
CompletedNCT00416702
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
An Open-Label, Single-Dose, Parallel-Group Study to Assess the Pharmacokinetics of 600 µg Indacaterol in Subjects With Impaired Hepatic Function in Comparison With Healthy Control Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAB149 |
Timeline
- Start date
- 2006-11-01
- Completion
- 2008-03-01
- First posted
- 2006-12-28
- Last updated
- 2008-06-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00416702. Inclusion in this directory is not an endorsement.